Summary
Mylan Laboratories Inc. CEO Robert J. Coury sees much of his generic pharmaceutical company's future tied to biologics -- generic biologics.
"Engineered biologics are three, four, five year max away," said the ebullient Coury, addressing questions following Mylan's annual shareholders meeting Friday at the Hilton Garden Inn, Cecil, Washinton County. "Generic biologics are a win for everyone, the patient, the insurer, the government as reimburser."See the full content of this document
Extract
Mylan Chief Touts Biologics
Biological products -- biologics -- according to the U.S. Food and Drug Administration, include a wide range of prod...
See the full content of this document
Sponsored links
